Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs

This study has been completed.
Sponsor:
Information provided by:
Nihon University
ClinicalTrials.gov Identifier:
NCT01271426
First received: January 5, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
  Purpose

To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.


Condition
Polypoidal Choroidal Vasculopathy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab

Resource links provided by NLM:


Further study details as provided by Nihon University:

Primary Outcome Measures:
  • Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab [ Time Frame: a month after injection ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA

white blood cell


Enrollment: 74
Study Start Date: April 2008
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

outpatients in hospital

Criteria

Inclusion Criteria:

  • Clinical diagnosis of Polypoidal choroidal vasculopathy
  • must have injection of Ranibizumab

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01271426

Locations
Japan
Surugadai Nihon university hospital
1-8-13 Kandasurugadai Chiyoda-ku, Tokyo, Japan, 101-8309
Sponsors and Collaborators
Nihon University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01271426     History of Changes
Other Study ID Numbers: NihonU-1
Study First Received: January 5, 2011
Last Updated: January 5, 2011
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Nihon University:
Polypoidal Choroidal Vasculopathy
Ranibizumab

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014